UMIN-CTR Clinical Trial

Recruitment status Completed
Unique ID issued by UMIN UMIN000030830
Receipt No. R000035189
Official scientific title of the study Steroids inhalation therapy in chronic eosinophilic pneumonia
Date of disclosure of the study information 2018/01/16
Last modified on 2018/01/16 (Ver. 1)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Official scientific title of the study Steroids inhalation therapy in chronic eosinophilic pneumonia
Title of the study (Brief title) Eosinophilic pneumonia
Region
Japan

Condition
Condition Eosinophilic pneumonia
Classification by specialty
Pneumology Clinical immunology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To examine lebel and site of inflamation in lung.
Basic objectives2 Others
Basic objectives -Others Efficacy of ICS in Eosinophilic Pnemonia.
Trial characteristics_1 Exploratory
Trial characteristics_2 Pragmatic
Developmental phase Not applicable

Assessment
Primary outcomes CD25 expression on CD4-positive T-lymphocytes was also increased (25.5 %) in the BALF compared to that on those in the peripheral blood (15.5 %).
Key secondary outcomes We tried many ICSs on remmission and acute phase but obtained enough effect in eosinophilic pneumonia.

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification NO
Dynamic allocation NO
Institution consideration Institution is not considered as adjustment factor.
Blocking NO
Concealment No need to know

Intervention
No. of arms 1
Purpose of intervention Diagnosis
Type of intervention
Maneuver
Interventions/Control_1 In December 1999, a 15-year-old girl was referred to Habikino hospital for evaluation of respiratory symptoms. BALF, Peripheral blood.process of treatments with ICS.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit

Not applicable
Age-upper limit

Not applicable
Gender Female
Key inclusion criteria Eosinophilic pneumonia, a case report.
Key exclusion criteria Nothing
Target sample size 1

Research contact person
Name of lead principal investigator Norihide Murayama
Organization Murayama Pediatrics
Division name Pediatrics
Address 3-2-33 Nagayoshi-Nagahara-Higashi Hirano-ku Osaka-shi Osaka Japan
TEL 06-6790-8835
Email norihide99@yahoo.co.jp

Public contact
Name of contact person Norihide Murayama
Organization Murayama Pediatrics
Division name Pediatrics
Address 3-2-33 Nagayoshi-Nagahara-Higashi Hirano-ku Osaka
TEL 06-6790-8835
Homepage URL
Email norihide99@yahoo.co.jp

Sponsor
Institute Murayama Pediatrics
Institute
Department

Funding Source
Organization Murayama Pediatrics
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2018 Year 01 Month 16 Day

Progress
Recruitment status Completed
Date of protocol fixation
1999 Year 12 Month 31 Day
Anticipated trial start date
1999 Year 12 Month 31 Day
Last follow-up date
2004 Year 07 Month 31 Day
Date of closure to data entry
2004 Year 07 Month 31 Day
Date trial data considered complete
2004 Year 07 Month 31 Day
Date analysis concluded
2004 Year 07 Month 31 Day

Related information
URL releasing protocol
Publication of results Unpublished
URL releasing results
Results Eosinophils were increased in both the BALF (65 %) and peripheral blood (33 %). HLADR expression was increased on CD4-positive T-lymphocytes in the BALF (62.8 %) compared to that on those in the peripheral blood (6.4 %). CD25 expression on CD4-positive T-lymphocytes was also increased (25.5 %) in the BALF compared to that on those in the peripheral blood (15.5 %).
Other related information We tried some ICS therapies for more than ten years. But I could not gain expected effect by any inhaled steroids.

Management information
Registered date
2018 Year 01 Month 16 Day
Last modified on
2018 Year 01 Month 16 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035189